Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease

Archives of Neurology

Volumn 55, Issue 11, 1998, Pages 1449-1455

  Clarke, Robert ^a   Smith, A David ^b,d   Jobst, Kim A ^b   Refsum, Helga ^c   Sutton, Lesley ^b   Ueland, Per M ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTINE; HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR DISEASE; VITAMIN BLOOD LEVEL; AGING; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; GENETIC POLYMORPHISM; MEMORY DISORDER; MIDDLE AGED; PREDICTION AND FORECASTING; RISK FACTOR;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; VASCULAR DISEASES; VITAMIN B 12;

EID: 0031597388     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.11.1449     Document Type: Article

References (41)

1. Esiri M, Wilcock GK. Cerebral amyloid angiopathy in dementia and in old age. J Neurol Neurosurg Psychiatry. 1986;49:1221-1226.
2. Nagy ZS, Esiri MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit of Alzheimer's disease. J Neuropathol Exp Neurol. 1997;56:165-170.
3. Snowden DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer's disease: the Nun Study. JAMA. 1997;277:813-817.
4. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular disease. J Neurol Neurosurg Psychiatry. 1997;63: 749-753.
5. Hachinsky V. Preventable senility: a call for action against the vascular dementias. Lancet 1992;340:645-647.
6. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlick RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
7. Hoffman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997; 345:151-154.
8. Kalaria RN. The blood brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev. 1992;4:226-260.
9. de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res. 1993;15:146-153.
10. Buee L, Hof PR, Bouras C, et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol Berl. 1994;87:469-480.
11. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer diseases. Annu Rev Med. 1996;47:387-400.
12. Kalaria RN. Arteriosclerosis, apolipoprotein E, and Alzheimer's disease. Lancet. 1997;349:1174.
13. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
14. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
15. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
16. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274: 1526-1533.
17. Nilsson K, Gustafson L, Faldt R, et al. Hyperhomocysteinemia: a common finding in a psychogeriatric population. Eur J Clin Invest. 1996;26:853-859.
18. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol. 1997;52:76-79.
19. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common genetic mutation in methylene tetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
20. Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet. 1994;343:829-830.
21. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet. 1992;340:1179-1183.
22. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), 2: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force of Alzheimer's Disease. Neurology. 1984;34:939-944.
24. Roth M, Huppert FA, Tym E, et al. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge, England: Cambridge University Press; 1988.
25. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:764-779.
26. Clarke R, Woodhouse P, Ulvik A, et al. Variability and determinants of plasma total homocysteine levels in an elderly population. Clin Chem. 1998;44:102-107.
27. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158-1159.
28. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025-1035.
29. Renvall MJ, Spindler AA, Ramsdell JW, Paskvan M. Nutritional status of free-living Alzheimer's patients. Am J Med Sci. 1989;298:20-27.
30. Kristensen MO, Gulmann NC, Christensen JEJ, Ostergaard K, Rasmussen K. Serum cobalamin and methylmalonic acid in Alzheimer dementia. Acta Neurol Scand. 1993;87:475-481.
31. Ball MJ, Fisman M, Hachinski V, et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet. 1985;1:14-16.
32. 12 in Alzheimer-type dementia. Age Ageing. 1984;13:101-105.
33. Karnaze DS, Carmel R. Low serum cobalamin levels in primary degenerative dementia: do some patients harbor atypical cobalamin deficiency states? Arch Intern Med. 1987;147:429-431.
34. 12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry. 1990;53:951-954.
35. 6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63:306-314.
36. Clarke R, Frost C, Leroy V, Collins R. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials: Homocysteine Lowering Trialist's Collaboration. BMJ. 1998;316:894-898.
37. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of adometionine (S-adenosylmethionine) in neurological disorders. Drugs. 1994;48:137-152.
38. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94:5923-5928.
39. Beal MF, Swartz KJ, Finn SF, Mazurek MF, Kowall NW. Neurochemical characterization of excitoxin lesions in the cerebral cortex. J Neurosci. 1991;11: 147-158.
40. Schmidt-Kastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 1991;40:599-636.
41. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet. 1994; 344:769-772.